4-Aminoquinazoline compounds
CN116867788BActive Publication Date: 2026-05-26ASTELLAS PHARMA INC
View PDF 7 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- ASTELLAS PHARMA INC
- Filing Date
- 2022-02-14
- Publication Date
- 2026-05-26
AI Technical Summary
Technical Problem
Current technologies are not effective in treating pancreatic cancer with KRAS G12D mutations, and there is a lack of effective G12D-mutant KRAS inhibitors.
Method used
A 4-aminoquinazoline compound of formula (I) was developed, exhibiting excellent inhibitory activity against G12D mutant KRAS, and was used as a pharmaceutical composition for the treatment of pancreatic cancer.
Benefits of technology
Compound (I) can effectively inhibit KRAS G12D mutations, providing a new treatment option for pancreatic cancer.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN116867788B_ABST
Abstract
This invention provides compounds useful as active ingredients in pharmaceutical compositions for the treatment of pancreatic cancer. The inventors studied compounds useful as active ingredients in pharmaceutical compositions for the treatment of pancreatic cancer and discovered that 4-aminoquinazoline compounds possess excellent G12D mutant KRAS inhibitory activity, making them suitable for use as therapeutic agents for pancreatic cancer, thus completing this invention. The 4-aminoquinazoline compound or its salt of this invention can be used as a therapeutic agent for pancreatic cancer.
Need to check novelty before this filing date? Find Prior Art